Comparing SG&A Expenses: Novo Nordisk A/S vs Bristol-Myers Squibb Company Trends and Insights

A Decade of SG&A Trends: Novo Nordisk vs. Bristol-Myers Squibb

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Novo Nordisk A/S and Bristol-Myers Squibb Company have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Novo Nordisk's SG&A expenses have surged by approximately 130%, reflecting a strategic expansion and increased market penetration. In contrast, Bristol-Myers Squibb's expenses have grown by about 36%, indicating a more conservative approach.

Key Insights

• Novo Nordisk: Starting at 26.76 billion in 2014, their SG&A expenses reached 61.60 billion by 2023, highlighting aggressive growth.
• Bristol-Myers Squibb: Their expenses rose from 5.70 billion in 2014 to 7.77 billion in 2023, showing steady but moderate growth.

These trends underscore the differing strategic priorities of these pharmaceutical giants, with Novo Nordisk focusing on rapid expansion and Bristol-Myers Squibb maintaining a steady course.